Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application

~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~

WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq:COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company’s common stock on the Nasdaq Global Market under the ticker symbol “ZSQR”. The new listing is expected to become effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly owned subsidiary of Coeptis and the Company will change its corporate name to Z Squared Inc.